Gene-Altering Treatment For Leukemia Could Soon Be Available
On Wednesday, the Food and Drug Administration (FDA) voted to recommend tisagenlecleucel, a gene-editing treatment for patients ages 3 to 25 with the most common form of childhood cancer in the United States, known as relapsed B-cell acute lymphoblastic leukemia (ALL). If the recommendation is accepted, it would be the first-ever gene therapy treatment available to…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “Gene-Altering Treatment For Leukemia Could Soon Be Available”
Sure is empty down here...